Thomas PouplinJulie Nguyen PouplinPham Van ToiNiklas LindegardhH. Rogier Van DoornTran Tinh HienJeremy FarrarM. Estée TörökTran Thi Hong ChauUCLCambridge University Hospitals NHS Foundation TrustMahidol University2018-05-032018-05-032011-07-01Antimicrobial Agents and Chemotherapy. Vol.55, No.7 (2011), 3624-362610986596006648042-s2.0-79959249152https://repository.li.mahidol.ac.th/handle/20.500.14594/12451The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings. Copyright © 2011, American Society for Microbiology. All Rights Reserved.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1128/AAC.01023-10